title: Management of lentigo maligna and lentigo maligna melanoma: seminars in surgical oncology.
abstract: Lentigo maligna (LM) and lentigo maligna melanoma (LMM) represent a character, histogenetic subclass of melanocytic malignancies. They often present with a prolonged phase of slow growth but once invasion has occurred, the prognostic features are identical to all other melanomas. These lesions occur primarily on the head and neck where they evolve from areas of pigmented staining to the more typical features identifiable with malignant melanomas on other skin surfaces. The treatment options and recent advances in management are reviewed.
authors.affiliation: Dermatologist, Clinical Associate Professor, Department of Oncology, University of Calgary, Alberta, Canada. arlette@johnarlette.com
authors.forename: John P
authors.initials: JP
authors.lastname: Arlette
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Trotter
authors.forename: Theresa
authors.initials: T
authors.lastname: Trotter
authors.forename: Claire L F
authors.initials: CL
authors.lastname: Temple
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D003452:Cryosurgery; D003937:Diagnosis, Differential; D006801:Humans; D018327:Hutchinson's Melanotic Freckle / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D016898:Interferon-alpha / Q000627:therapeutic use; D053685:Laser Therapy; D008545:Melanoma / Q000473:pathology*; D018328:Melanoma, Amelanotic / Q000601:surgery; D008875:Middle Aged; D011379:Prognosis; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*
chemical_list: D000276:Adjuvants, Immunologic; D016898:Interferon-alpha